Proteomic biomarkers of recovered heart function

Abstract

Aims Chronic heart failure is a costly epidemic that affects up to 2% of people in developed countries. The purpose of this study was to discover novel blood proteomic biomarker signatures of recovered heart function that could lead to more effective heart failure patient management by both primary care and specialty physicians. Methods and results The discovery cohort included 41 heart transplant patients and 20 healthy individuals. Plasma levels of 138 proteins were detected in at least 75% of these subjects by iTRAQ mass spectrometry. Eighteen proteins were identified that had (i) differential levels between pre‐transplant patients with end‐stage heart failure and healthy individuals; and (ii) levels that returned to normal by 1 month post‐transplant in patients with stable heart function after transplantation. Seventeen of the 18 markers were validated by multiple reaction monitoring mass spectrometry in a cohort of 39 heart failure patients treated with drug therapy, of which 30 had recovered heart function and 9 had not. This 17‐protein biomarker panel had 93% sensitivity and 89% specificity, while the RAMP® NT‐proBNP assay had the same specificity but 80% sensitivity. Performance further improved when the panel was combined with NT‐proBNP, yielding a net reclassification index relative to NT‐proBNP of 0.28. Conclusions We have identified potential blood biomarkers of recovered heart function by harnessing data from transplant patients. These biomarkers can lead to the development of an inexpensive protein‐based blood test that could be used by physicians to monitor response to therapy in heart failure, resulting in more personalized, front‐line heart failure patient management.

Discovery of novel plasma protein biomarkers to predict imminent cystic fibrosis pulmonary exacerbations using multiple reaction monitoring mass spectrometry

“…Preprocessing of the MRM-MS data involved several steps as described previously 21. Peptides that did not pass quality control metrics and those present in <75% of the patient samples were eliminated from the analysis.…”

Proteomics of Drug-Resistant Cancer Biomarkers

“…In conclusion, the iTRAQ technology reduces the influence of system error (ion inhibition effect, background noise and equipment conditions) down to minimum and has incomparable advantages relative to other methods. The iTRAQ technology can label all proteins including phosphorylated proteins, glycosylated proteins and post-translational modifications of proteins, which provides more detailed quantitative information for the discovery and identification of multiple sample analysis and disease markers in different periods of time [7,9]. In addition, the incidence and mortality of cancer are faster growing compared with any other disease in the world.…”

Analysis of the plasma proteome using iTRAQ and TMT‐based Isobaric labeling

“…In relation to treatment and restoring the function of the heart, plasma profiles have been determined to compare different methods in aortic surgery, to find markers of calcific aortic stenosis in patients after aortic valve replacement, and find signatures of both cardiac allograft vasculopathy and recovered heart function . Other investigations of the heart include a study of mitral valve prolapse, where Tan et al evaluated whether plasma biomarkers could be used in the evaluation of mitral regurgitation in patients.…”

“…190 Some applications in which the analysis of the plasma proteome was made in relation to transplants were mentioned in the section on circulations and cardiovascular risk. 121,191 While in such specific instances it may be difficult to find sizeable study cohorts, liver, kidney, and stem cell transplantation have also been investigated. Freue et al used LC-MALDI-TOF/TOF and iTRAQ to identify plasma proteomic signatures of allograft rejection.…”